Evidence map›Paper›PMID 41181614›Full record

ArticleACG case reports journal2025

Gastric and Duodenal Mucosal Healing With Risankizumab in Upper Gastrointestinal Crohn's Disease.

Mark Chatto, Rocio Sedano, Vipul Jairath

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mark ChattoDivision of Gastroenterology, Western University, London, Ontario, Canada.
Rocio SedanoDivision of Gastroenterology, Western University, London, Ontario, Canada.
Vipul JairathDivision of Gastroenterology, Western University, London, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are very limited data on the efficacy of medical therapies for upper gastrointestinal Crohn's disease (CD), and no data exist for the efficacy of IL-23 p19 inhibition on upper gastrointestinal CD. We present the case of a 21-year-old man with severe gastric and duodenal CD, who demonstrated complete clinical and endoscopic response to risankizumab after 28 weeks of therapy.

Indexed as

endoscopic responserisankizumabupper GI Crohn's disease

Identifiers

PMID41181614
PMCPMC12574531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.